The 20 Best Diffuse Midline Glioma H3 K27M-Mutant Doctors Near Me in District of Columbia, US

Roger Packer is a Pediatrics provider practicing medicine in Washington, Washington, D.c.. Dr. Packer is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Brain Tumor, Diffuse Midline Glioma H3 K27M-Mutant, Medulloblastoma, and Gliomatosis Cerebri.

Lindsay Kilburn, MD, comes to Children's National Hospital from Texas Children’s Hospital in Houston, TX, where she was an assistant professor of pediatrics in the neuro-oncology and pharmacology programs. Dr. Kilburn graduated with a degree in Environmental Sciences from the University of Virginia. After graduating from Eastern Virginia Medical School, she completed her pediatric training at the Children’s Hospital of The King’s Daughters in Norfolk, VA, and her hematology/oncology fellowship at Texas Children’s Hospital/Baylor College of Medicine in Houston, TX. She also has received training in pharmacology from both Thomas Jefferson University in Philadelphia and the Baylor College of Medicine in Houston. Dr. Kilburn is an associate professor, pediatrics at George Washington University School of Medicine. Her research focuses on the development and evaluation of new therapeutic agents for children with pediatric brain tumors through clinical trials. She is committed to the improvement of palliative and supportive care. Dr. Kilburn grew up outside of Philadelphia and is married with young twins. Outside of work, she enjoys sailing, hiking, and traveling with her family. Dr. Kilburn is rated as a Distinguished provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, Glioma, and Optic Glioma. Dr. Kilburn is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2009 and Pediatrics: American Board Of Pediatrics, 2004.

Victoria J. Croog, M.D., Department of Radiation Oncology at the Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, as well as a clinical associate in the Department of Radiation Oncology at The Johns Hopkins Hospital. Dr. Croog has expertise in breast cancer, gastrointestinal cancer, gynecologic cancer, brain cancer and tumors of the central nervous system. Dr. Croog earned her medical degree from Harvard Medical School. She completed an internship and a residency in radiation oncology at Memorial Sloan-Kettering Cancer Center. Dr. Croog is involved with several committees at Sibley Memorial Hospital, including the Medical Executive Committee, the IRB/Research Review Committee, the Cancer Committee and the Radiation Safety Committee. She is also a member of the American Society of Clinical Oncology and the American Society of Radiation Oncology. Dr. Croog has been repeatedly named a Top Doctor by Washingtonian Magazine. Dr. Croog has been published in numerous peer-reviewed journals and has presented research at various conferences, such as the American Society of Clinical Oncology’s annual meeting. Make A Gift LinkedIn https://www.linkedin.com/in/victoria-croog-88a31759. Dr. Croog is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 24 other conditions, according to our data. Her clinical expertise encompasses Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Breast Cancer, and Pancreatic Cancer. Dr. Croog is board certified in American Board Of Radiology.

Matthew Ladra, M.D., M.P.H., leads the dedicated pediatric team for the Johns Hopkins Proton Therapy Center and is the director of pediatric radiation oncology for the Johns Hopkins Kimmel Cancer Center, a clinical collaboration with Children’s National Hospital, where Dr. Ladra serves as faculty in the department of pediatric oncology. He is also an assistant professor of radiation oncology and molecular radiation sciences at the Johns Hopkins School of Medicine. Listen Dr. Ladra's Cancer Matters podcast episode to learn more about his work. Previously, Dr. Ladra served as the director of pediatric radiation at the Provision Center for Proton Therapy in Tennessee. He also completed a 2-year fellowship in pediatric proton therapy at the Massachusetts General Hospital’s Francis H. Burr Proton Center. Dr. Ladra is one of a handful of radiation oncologists whose research and clinical efforts focus exclusively on pediatric patients. He is frequently invited to speak on pediatric radiation oncology topics internationally and across the U.S. and has published extensively on the subject through original research book chapters and review articles. Dr. Ladra’s research efforts focus mainly on pediatric rhabdomyosarcoma treatment, early phase clinical trials involving radiation and non-chemotherapeutic agents, and reducing neurocognitive toxicity for pediatric brain tumor patients. LinkedIn https://www.linkedin.com/in/matthew-ladra-3094a316. Dr. Ladra is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Rhabdomyosarcoma, Muscle Invasive Bladder Cancer, Adult Soft Tissue Sarcoma, and Ependymoma. Dr. Ladra is board certified in American Board Of Radiology.

Hasan R. Syed, MD, was born in Morganton, NC and raised outside of Washington, D.C. He graduated as valedictorian of his high school class and attended Virginia Commonwealth University (VCU) as a Presidential Scholar in the Honors College. While in Richmond, he majored in Biomedical Engineering and graduated summa cum laude. He remained at VCU to complete his medical degree, where he was elected to the Alpha Omega Alpha Honor Medical Society. During this time, Dr. Syed was awarded funding through the Office of Research for a master’s degree to investigate cancer stem cell biology at King's College London. Dr. Syed completed his internship and neurological surgery residency at Georgetown University under Kevin McGrail, MD He received numerous awards during his training, including the resident traveling fellowship from the AANS/CNS Section on pediatric neurosurgery, and published manuscripts, book chapters and delivered oral presentations on both adult and pediatric brain and spinal disorders. Following completion of his post-graduate training, he relocated to Chicago to complete a prestigious subspecialty fellowship in pediatric neurosurgery at Ann & Robert H. Lurie Children's Hospital, Northwestern University under renowned pediatric neurosurgeon Tad Tomita, MD After spending three years at the University of Virginia as an assistant professor and associate residency program director, Dr. Syed joined Children’s National Hospital as an associate professor and fellowship director with a focus in pediatric neurosurgery. His clinical interests include brain and spinal tumors, hydrocephalus, craniosynostosis, Chiari malformation, epilepsy, spinal dysraphism, spasticity, craniocervical spinal disorders, peripheral nerve injuries and Moyamoya disease. He also has a strong interest in minimal access surgeries for brain and spinal disorders in pediatric patients. Dr. Syed is certified by the American Board of Neurological Surgery (ABNS) and the American Board of Pediatric Neurosurgery (ABPNS). Outside of work, his interests include traveling and spending time with his family in Washington, D.C. Dr. Syed is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Hydrocephalus, Metopic Ridge, Craniosynostosis, Spinal Fusion, and Laminectomy. Dr. Syed is board certified in American Board Of Neurological Surgery, 2020.

"Eugene (Gene) Hwang, MD, is chief of the Division of Oncology at Children’s National Hospital in Washington, D.C. He is also part of the Children's National Hospital pediatric neuro-oncology team, focusing on treating children with brain tumors. Dr. Hwang has developed and led many novel early phase therapeutic clinical trials with a focus on immunotherapeutic trials, and he also leads trials focused on gene therapy and new, targeted agents. He is the site Principal Investigator of the Pediatric Brain Tumor Consortium, where he is the co-chair of the Immunotherapy Working Group. He serves on grant review committees and on the scientific advisory boards of several large foundations. For each patient, Dr. Hwang carefully considers the best possible options for treatment, trying new, cutting edge treatments coupled with the best available known therapies. Dr. Hwang is not only dedicated to finding a cure for cancer, but also to making the current treatments as safe as possible for children: ""We often focus on curing the children - that's the number one goal - but we also need to pay attention to the toxicity of these treatments, and what quality of life the children will have after treatment."" Dr. Hwang is involved in several international efforts to study how to best mitigate treatment side effects. In the meantime, Dr. Hwang makes sure he is doing everything he can to combat pain, dizziness, fatigue and other common side effects of cancer treatments by leveraging the multidisciplinary team approach of Children's National. He sees this as something the organization does exceptionally well, and thinks that having so many people focus on a single patient in a single visit is crucial to well-being during cancer treatment.". Dr. Hwang is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Pineocytoma, Glioma, Medulloblastoma, and Pineoblastoma. Dr. Hwang is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2009 and Pediatrics: American Board Of Pediatrics, 2005.

Robert Keating, MD, is currently a McCullough distinguished professor, interim senior vice president, Neuroscience and Behavioral Medicine Center and chief of Neurosurgery at Children’s National Hospital. A graduate of Georgetown University Medical School, he completed a neurosurgery residency and fellowship in pediatric neurosurgery/craniofacial surgery at the Albert Einstein and Montefiore Medical Center in the Bronx, NY. Following his training, Dr. Keating served in the U.S. Navy and was stationed at the Oakland Naval Hospital serving as the chief from 1991-1994. After his time in the Navy, he returned to the Bronx where he was on staff at Montefiore Medical Center as well as the Bronx Municipal Hospital Center for two years before coming back to Washington, D.C., in 1996 to join the faculty at Children’s National Dr. Keating's past appointments include the president of the medical staff at Children’s National, as well as head of credentials. He currently maintains a busy practice of pediatric neurosurgery, with an emphasis on tumors, Chiari malformations, craniofacial reconstruction, spinal dysraphism, spasticity and brachial plexus surgery. As a member of the American Society of Pediatric Neurosurgery and International Society of Pediatric Neurosurgery, he has published and presented extensively in the field. His publications include the previous texts, “An Atlas of Orbitocranial Surgery” and “Tumors of the Pediatric Nervous System” (2nd edition published in 2013), with current work on Neurosurgical Operative Atlas, (2nd ed. Goodrich JT, and Keating RF, Thieme) due for publication in 2018. He is also chair, medical advisory committee on the Board of the American Syringomyelia Alliance Project as well as a founding member of the Posterior Fossa Society and maintains long-standing membership in the CNS, AANS, ASPN and ISPN. Dr. Keating is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Craniosynostosis, Metopic Ridge, Chiari Malformation Type 1, Posterior Fossa Decompression, and Craniectomy. Dr. Keating is board certified in Neurological Surgery: American Board Of Neurological Surgery, 2000 and Neurological Surgery: American Board Of Neurological Surgery, 1993.

Luca Szalontay is a Pediatric Hematologist Oncology provider practicing medicine in Washington, Washington, D.c.. She has been practicing medicine for over 17 years. Dr. Szalontay is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 2 other conditions, according to our data. Her clinical expertise encompasses Glioma, Diffuse Midline Glioma H3 K27M-Mutant, Medulloblastoma, and Brain Stem Cancer. Dr. Szalontay is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2021 and Pediatrics: American Board Of Pediatrics, 2015.

Brian R. Rood, MD, is the director of clinical neuro-oncology and the medical director of the Brain Tumor Institute at Children's National Hospital. Dr. Rood is also a principal investigator in the Center for Cancer and Immunology Research at Children's National Research Institute and a professor of pediatrics at the George Washington University School of Medicine and Health Sciences and adjunct professor at the Fralin Biomedical Research Institute at Virginia Tech. He received a Bachelor of Arts in English Literature from The Pennsylvania State University and completed medical school at Jefferson Medical College. He completed his pediatric residency training at the University of Vermont. Dr. Rood received his pediatric hematology/oncology training at Children's National. He joined the faculty of Children’s National in 2002 after completing a fellowship in pediatric hematology/oncology, as well as a research fellowship in the molecular biology of brain tumors, both at Children’s National and Children’s National Research Institute. Currently, Dr. Rood’s research focuses on the application of proteomics in cancer biology investigation, neoantigen identification and biomarker development. He has also been studying the contribution of germline microsatellite genotypes to pediatric brain tumor predisposition. He currently serves as the executive co-chair of the Children’s Brain Tumor Network, an international consortium of 28 institutions that maintains the world’s largest pediatric brain tumor tissue and data repository, which are freely provided to the research community to support the development of groundbreaking clinical trials through data-driven precision medicine. Dr. Rood has two children. His favorite pastimes include designing and building furniture, sailing, reading, and playing the mandolin. Dr. Rood is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, and Diffuse Midline Glioma H3 K27M-Mutant. Dr. Rood is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2002 and Pediatrics: American Board Of Pediatrics, 1998.

Adriana Sheridan is a Pediatrics provider practicing medicine in Washington, Washington, D.c.. She has been practicing medicine for over 20 years. Dr. Sheridan is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her clinical expertise encompasses Diffuse Midline Glioma H3 K27M-Mutant, Medulloblastoma, Pediatric Low-Grade Glioma (pLGG), and Glioma. Dr. Sheridan is board certified in Pediatrics: American Board Of Pediatrics, 2024, Pediatric Hematology-Oncology: American Board Of Pediatrics, 2021, and The Royal College Of Physicians And Surgeons Of Canada, 2015.

Abdullah Feroze, MD, is a neurosurgeon at Children’s National Hospital and an assistant professor of neurosurgery at George Washington University. Dr. Feroze specializes in the care of children and adults with complex neurosurgical conditions. His expertise spans the full spectrum of pediatric neurosurgical care, including: Management of brain and spine tumors Congenital anomalies Hydrocephalus Spine disorders Epilepsy Spasticity Vascular anomalies He serves as a tireless advocate for his patients and their families, providing not only surgical excellence, but unwavering guidance and support through their respective treatment journeys. One of a select few neurosurgeons in North America with specialized training in both pediatric and adult open cerebrovascular and endovascular techniques, he has a keen interest in providing comprehensive and compassionate treatment for a wide range of congenital and acquired cerebrovascular diseases, including: Brain aneurysms Arteriovenous malformations Idiopathic intracranial hypertension Vein of Galen malformations Stroke Moyamoya disease Dr. Feroze employs a tailored approach to each patient's unique needs in conjunction with a dedicated multidisciplinary team, ensuring the most effective and safest possible outcomes. A graduate of the Stanford University School of Medicine, Dr. Feroze completed neurosurgical residency at the University of Washington/Harborview Medical Center and subsequent fellowships at Harvard Medical School (Brigham & Women’s Hospital/Boston Children’s Hospital) and Children’s National. He is an active member of the American Association of Neurological Surgeons, Society for Neurointerventional Surgery and the International Society of Pediatric Neurosurgery. He remains involved in the realm of health policy advocacy, with prior engagements at the World Health Organization and the White House. His research efforts in brain tumor immunotherapy, global health disparities and vascular neurosurgery have been recognized in multiple publications including The Lancet, Forbes Magazine, Nature Biotechnology, and Science Translational Medicine. In his spare time, he enjoys tennis, mountaineering and gardening. Publications: ORCID PUBMED. Dr. Feroze is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Central Pain Syndrome, Brain Tumor, Gliomatosis Cerebri, Craniectomy, and Endovascular Embolization. Dr. Feroze is board certified in American Board Of Pediatrics, 2022.